OBIO Stock Summary and Trading Ideas (Orchestra Biomed Hldgs | NASDAQ:OBIO)

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Orchestra Biomed Hldgs trades on the NASDAQ stock market under the symbol OBIO.

As of May 10, 2024, OBIO stock price declined to $4.71 with 16,547 million shares trading.

OBIO has a beta of 0.61, meaning it tends to be less sensitive to market movements. OBIO has a correlation of 0.01 to the broad based SPY ETF.

OBIO has a market cap of $168.41 million. This is considered a Micro Cap stock.

Last quarter Orchestra Biomed Hldgs reported $262,000 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-728,000 and exceeded earnings estimates by $.01.

The top ETF exchange traded funds that OBIO belongs to (by Net Assets): VTI, VXF, IWM, IWO, SCHA.

OBIO has underperformed the market in the last year with a return of -72.4%, while the SPY ETF gained +27.8%. In the last 3 month period, OBIO fell short of the market, returning -33.9%, while SPY returned +4.2%. However, in the most recent 2 weeks OBIO has outperformed the stock market by returning +7.3%, while SPY returned +2.5%.

OBIO support price is $4.63 and resistance is $5.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OBIO stock will trade within this expected range on the day.